NSE: VIYASH · BSE: 512529 · ISIN INE807F01027
Viyash Scientific Limited stock analysis
Viyash Scientific Limited ranks #1041 in the TickerSutra evidence-ranked universe with a score of 57/100 and 95% data confidence. The latest captured fundamentals show ROCE of 13.4%, quarterly sales growth of 19.5% and quarterly profit growth of 103.6%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.17×
- 34% three-year sales CAGR
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- CFO/EBITDA is below 0.6×
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹1,413cr | ₹109cr | ₹45cr | 8.0% |
| 2023 | ₹1,421cr | ₹12cr | ₹-122cr | 0.8% |
| 2024 | ₹1,370cr | ₹61cr | ₹-30cr | 4.5% |
| 2025 | ₹3,007cr | ₹387cr | ₹16cr | 13.0% |
| 2026 | ₹3,420cr | ₹653cr | ₹225cr | 19.0% |
| TTM | ₹3,575cr | ₹711cr | ₹267cr | 20.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Viyash Scientific Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineGeneral UpdatesNSE · 18 Sept 2026Viyash Scientific Limited has informed the Exchange about Allotment of ESOP
RoutineViyash Scientific Ltd - 512529 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSBSE · 18 Sept 2026Allotment of ESOP
MANAGEMENT COMMENTARY
Signals from filed documents
Profit after tax increased by 115% year -on-year to Rs. 20.4 crores in Q1 FY’26, reflecting the benefits of our continuous focus on balance sheet strengthening and debt reduction. Pursuant to the composite scheme of amalgamation, and upon receipt of necessary approvals during the quarter ended 30th June, company has granted Rs.
But last few quarters, we see good potential to grow volume. So, looking at the volume, looking at all our product launches, we are confident to approach to that. Both markets are doing extremely well.
Because from last year, we are seeing the volume growth. Earlier, you know, Turkey used to be only price increase. But last few quarters, we see good potential to grow volume.
So, in 4 quarters, we have gone from a leveraged combined entity to a company which is virtually debt- free on a net basis. This gives us tremendous opportunity with respect to brownfield expansion as well as exploring inorganic opportunities. Coming to segment performance: Our Animal Health Formulation business continues to grow very strong across all regions, and we believe the growth will continue with our continu
We want to focus on new product development on molecules which have potential across multiple geographies. For Human Formulations , as I mentioned earlier, we will continue to focus on first -to-file opportunities, with focus more on high-potent complex formulations, with fully backward integration support on key molecules. In API and CDM O focus is on day 1 launch, complex molecules, expanding our CDM O business to
We are also seeing strong growth in domestic market as well (up 60%), and here we are looking to expand our fieldforce and product portfolio further to grow aggressively. Coming to Human formulation: Our US business has grown 60% showing results of our efforts to moving towards backward - integrated, more complex products. That is now translating into real growth along with profitability improvement.
General APIs are going to price erode by 95%. When it comes to oncology or these high potent , we can expect at least 50 %-60% price erosion. And API contribution is around 20% of the formulation thing.
When you develop and file the product, Viyash Scientific Limited August 12, 2026 Page 16 of 17 you have to start filing one product. And that country, when the regulator is reviewing, it extend to other markets. So, this is going to be the bigger portion, not only Bio ForLife products.
And just a couple of questions from my side. First is as Viyash moves from integration now into much more complex phase of R&D, manufacturing, geographic expansion and M&A, hopefully. What are the few non-negotiable principles that management uses to ensure that growth does not compromise execution, quality and cash generation?
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…